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A comprehensive analysis of somatic and germline mutations related to DNA mismatch–repair (MMR) genes can
clarify the prevalence and mechanism of inactivation in colorectal carcinoma (CRC). In the present study, 257
unselected patients referred for CRC resection were examined for evidence of defective DNA MMR. In particular,
we sought to determine the frequency of hereditary defects in DNA MMR in this cohort of patients. MMR status
was assessed by testing of tumors for the presence or absence of hMLH1, hMSH2, and hMSH6 protein expression
and for microsatellite instability (MSI). Of the 257 patients, 51 (20%) had evidence of defective MMR, demon-
strating high levels of MSI (MSI-H) and an absence of either hMLH1 ( ) or hMSH2 ( ). All threenp 48 np 3
patients lacking hMSH2, as well as one patient lacking hMLH1, also demonstrated an absence of hMSH6. DNA
sequence analysis of the 51 patients with defective MMR revealed seven germline mutations—four in hMLH1 (two
truncating and two missense) and three in hMSH2 (all truncating). A detailed family history was available for 225
of the 257 patients. Of the seven patients with germline mutations, only three had family histories consistent with
hereditary nonpolyposis colorectal cancer. Of the remaining patients who had tumors with defective MMR, eight
had somatic mutations in hMLH1. In addition, hypermethylation of the hMLH1 gene promoter was present in 37
(88%) of the 42 hMLH1-negative cases available for study and in all MSI-H tumors that showed loss of hMLH1
expression but no detectable hMLH1 mutations. Our results suggest that, although defective DNA MMR occurs
in ∼20% of unselected patients presenting for CRC resection, hereditary CRC due to mutations in the MMR
pathway account for only a small proportion of patients. Of the 257 patients, only 5 (1.9%) appear to have
unequivocal evidence of hereditary defects inMMR. The epigenetic (nonhereditary) mechanism of hMLH1 promoter
hypermethylation appears to be responsible for themajority of the remaining patients whose tumors are characterized
by defective DNA MMR.
Introduction
Familial polyposis (FAP [MIM 175100]) and heredi-
tary nonpolyposis colorectal cancer (HNPCC [MIM
114500]) are two common autosomal dominant dis-
orders predisposing to the development of colorectal
cancer (CRC) (Bellacosa et al. 1996; Khine et al. 1996;
Fante et al. 1997; Lynch et al. 1997; Soravia et al.
1997). FAP is characterized by the presence of hundreds
to thousands of adenomatous polyps. HNPCC, on the
other hand, is characterized by the occurrence of co-
lorectal cancer at an early age (fourth to sixth decade),
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a tendency to develop multiple primary cancers, and
an increased risk for the development of certain other
cancers, particularly endometrial and stomach cancer
(Lynch and Lynch 1995). It is generally easier to as-
certain a diagnosis of FAP than HNPCC, because most
patients with FAP eventually develop profuse polyposis
and, sometimes, other tumor types (e.g., osteomas and
periampullary carcinomas) that can aid in the diag-
nosis. Patients with HNPCC, on the other hand, lack
distinctive phenotypic features. Consequently, the di-
agnosis of HNPCC has historically been based on fam-
ily history. As a result, the true incidence of this disease
and the underlying molecular defects have been difficult
to establish. The estimated percentage of CRC cases
caused by HNPCC has varied from ∼0.5% to 10%
(Aaltonen et al. 1994b; Bellacosa et al. 1996; Brassett
et al. 1996; Evans et al. 1997; Peel et al. 2000).
The Amsterdam criteria (AC) were established in the
early 1990s to define the clinical criteria used to identify
patients with HNPCC (Vasen et al. 1991). These criteria
Cunningham et al.: Mismatch Repair in Colon Cancer 781
call for the occurrence of verifiable colorectal cancer in
three individuals (one of whom is the first-degree rel-
ative of the other two), the presence of cancer in at least
two successive generations, and an age at onset of CRC
of !50 years in at least one case. These criteria were
created to help identify families that have a high prob-
ability of having an hereditary form of colorectal cancer
not accompanied by polyposis (i.e., HNPCC). It was
understood, however, that families classified, on the ba-
sis of the AC, as having HNPCC might represent a
heterogeneous group with respect to the underlying ba-
sis of disease. Nonetheless, it was an important step in
attempting to determine the genetic basis of colorectal
cancer.
For clinical purposes, however, the AC are now rec-
ognized to be too restrictive, since other malignancies
(e.g., gastric and endometrial) frequently occur in pa-
tients with HNPCC and may be the presenting cancers
in such families (Beck et al. 1997b; Bapat et al. 1999).
As a result, several modifications that include consid-
eration of extracolonic malignancies in the diagnosis
have been suggested (Beck et al. 1997b; Bapat et al.
1999; Vasen et al. 1999). In addition to family history,
however, there are now laboratory approaches that may
aid in establishing this diagnosis in a subset of patients
with HNPCC. These have arisen from studies that re-
vealed the underlying genetic defect in many—but not
all—families diagnosed with HNPCC; namely, defective
DNA-mismatch repair (MMR).
Of the seven humanDNAMMR genes that have been
identified (hMLH1, hMSH2, hMSH3, hMSH6, hPMS1,
hMLH3, and hPMS2), germline mutations have been
identified in all but two (hMSH3 and hMLH3) in fam-
ilies with HNPCC (Fishel et al. 1993; Lindblom et al.
1993; Papadopoulos et al. 1994, 1995; Lipkin et al.
2001). Germline mutations are detected most frequently
in patients with HNPCC who satisfy the AC, although
some individuals who do not fulfill these criteria also
carry germline mutations (Beck et al. 1997a). The ma-
jority of these HNPCC patients have mutations in either
hMLH1 or hMSH2, with less frequent involvement of
other genes. However, there are also some families with
HNPCC in which mutations in MMR genes have not
been identified and whose tumors do not demonstrate
phenotypic evidence of defective DNA MMR—that is,
they do not demonstrate either the presence of tumor
microsatellite instability (MSI) or the absence of protein
expression for one of the genes involved in DNAMMR
(Aaltonen et al. 1994a; Craanen et al. 1996; Moslein
et al. 1996; Lamberti et al. 1999; Peel et al. 2000).
MSI is a phenotypic indicator of defective DNA
MMR and is detected in tumors from HNPCC patients,
as well as in a low percentage of various sporadic can-
cers, such as colon, endometrial, and stomach cancer
(Aaltonen et al. 1993; Han et al. 1993; Ionov et al.
1993; Thibodeau et al. 1993; Burks et al. 1994; Duggan
et al. 1994; Keller et al. 1995; Akiyama et al. 1996;
Caduff et al. 1996; Battista et al. 1997; Gurin et al.
1999). In CRC, several phenotypes of MSI have been
defined: MSI-H (MSI in 130% of loci examined), MSI-
L (MSI in !30% loci examined), and MSS (microsat-
ellite stable, showing no instability at any site) (Boland
et al. 1998). Sporadic CRC with the MSI-H phenotype
has distinct clinicopathological features, including a ten-
dency to occur in the proximal colon, high frequency
in females, high grade, diploidy, and improved overall
survival compared with those without widespread mi-
crosatellite instability (Thibodeau et al. 1993; Fujita et
al. 1996; Sankila et al. 1996; Lynch et al. 1997). Almost
all such cases are due to functional loss of either hMLH1
or hMSH2. The MSI-L phenotype, on the other hand,
is not associated with these clinicopathological features
or with altered hMLH1 or hMSH2. The majority of
HNPCC-associated tumors are characterized by MSI-
H, whereas MSI-H, MSI-L, and MSS are found in spo-
radic CRC.
In spite of numerous studies on the frequency of de-
fective MMR in CRC, there have been few studies ex-
amining the frequency of inherited CRC due to defective
MMR in a series of patients not selected for family
history of colon cancer. Aaltonen et al. (1998), in a study
of 509 consecutive Finnish patients with colorectal can-
cer, found that inherited defects in MMR occurred in
∼2% of the cases studied. In their study, all cases were
examined for evidence of defective MMR, irrespective
of family history; however, half (5/10) of the germline
mutations identified were determined to originate from
a single common founder mutation, found in 130 fam-
ilies in Finland and Sweden. No other population-based
studies have been performed. The purpose of the present
study was to determine the frequency of defective DNA
MMR, as well as the underlying mechanism, in an un-
selected prospective series of colorectal cancers in pa-
tients referred to the Mayo Clinic. More specifically, we
sought to determine the frequency of inherited defects
in this series of patients. The present article details the
first set of 257 unselected cancers in an ongoing pro-
spective study. Tumors were examined for the presence
or absence of: (a) tumor MSI; (b) hMLH1, hMSH2,
and hMSH6 protein expression; (c) hMLH1, hMSH2,
and hMSH6 gene mutations; and (d) hMLH1 and
hMSH2 promoter hypermethylation. Patients’ family
histories were obtained to determine the familial com-
ponent, and the clinical characteristics of the patients
were analyzed.
Material and Methods
Patient Population
A total of 514 patients underwent surgical resection
for CRC at the Mayo Clinic during a 1.5-year period,
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from December, 1995, to April, 1997. Four hundred and
sixty-six patients were approached about the study, and
267 (57.3%) consented to participate. Of the consenting
patients, seven had inadequate cancer tissue available
for study, one had only paraffin-embedded tissue avail-
able, and two had only metastatic disease. These patients
were not included, leaving 257 available for further
study. Of the 257 patients, 237 were white (92%), 4
(1.5%) were of African American descent, 3 (1%) were
of Hispanic origin, and 13 (5%) had no designated race.
Seventy-five percent (192) came from Minnesota (103),
Iowa (32), Wisconsin (10), North Dakota (6), South
Dakota (7), or Illinois (34). The remainder came from
an additional 27 states within the continental United
States.
Patient chart reviews were performed to obtain clinical
characteristics of the tumor, including tumor site, stage,
and age at diagnosis. For tumor site, tumors of the prox-
imal colon were defined as those CRCs occurring in the
cecum, the ascending colon, or the transverse colon. Dis-
tal tumors were defined as those occurring in the de-
scending or sigmoid colon or in the rectum. Family his-
tories were documented by telephone follow-up for 225
of the 257 patients, through use of a detailed question-
naire. On the basis of this information, three- to four-
generation pedigrees were constructed. On the basis of
the presence of family history of CRC, patients fulfilling
the AC ( ) (Vasen et al. 1991) and patients fulfillingnp 7
the modified AC ( , including the seven AC) (Vasennp 9
et al. 1999) were identified. For the purposes of the
present study, an HNPCC-related cancer included can-
cers of the colon, small bowel, ureter, endometrium, and
renal pelvis (Vasen et al. 1999). FAP was diagnosed in
three patients, and chronic ulcerative colitis (CUC) was
diagnosed in another four; these patients were not ex-
cluded from the analysis.
DNA Extraction
DNAwas extracted from frozen or paraffin-embedded
tissues, as described elsewhere (Thibodeau et al. 1998).
In brief, DNA from microdissected frozen tissue sections
(10 mm) was extracted by a standard phenol/chloroform
procedure. For tumor DNA, only those areas containing
170% tumor cells were used. For DNA extraction from
paraffin-embedded tissues, the Qiamp Tissue kit (Qia-
gen, Inc.) was used, according to the manufacturer’s in-
structions. The corresponding normal control DNA for
each patient was derived from peripheral blood. For
these specimens, DNA was extracted using the Puregene
nucleic acid–isolation kit (Gentra).
Microsatellite Instability
Paired normal and tumor DNA were analyzed for
microsatellite instability with six dinucleotide micro-
satellite markers (D5S346, TP53, D18S34, D18S49,
D18S61, and ACTC) and one mononucleotide repeat
(BAT 26). PCR and gel electrophoresis were performed
as described by Thibodeau et al. (1993). Tumors were
classified as MSH-H if 30% markers demonstrated
instability, as MSH-L if !30% demonstrated MSI, and
as MSS if no marker exhibited MSI (Boland et al. 1998;
Thibodeau et al. 1998). These studies were performed
with DNA isolated from paraffin-embedded material.
Immunohistochemical Analysis
The expression of hMLH1, hMSH2, and hMSH6 pro-
tein was assessed as described elsewhere (Thibodeau et
al. 1998). In brief, 5-mm tissue sections from formalin-
fixed, paraffin-embedded tissue were stained with anti-
body to hMLH1 (clone G168 728; 1 mg/ml [Phar-
Mingen]), hMSH2 (clone FE11; 0.5 mg/ml [Oncogene
Science]), and hMSH6 (clone 44, 0.5 mg/ml [Transduc-
tion Laboratories]). Tumor cells that showed an absence
of nuclear staining in the presence of normal positive
staining in surrounding cells were interpreted as having
an absence of expression of these proteins.
Sequencing
Exons 1–19 of hMLH1 and/or exons 1–16 of hMSH2
were sequenced in all tumors lacking expression of
hMLH1 ( ) or hMSH2 ( ), using the Ther-np 48 np 3
moSequenase kit (Amersham), essentially as described
by Moslein et al. (1996). For hMSH6, only exon 5 was
sequenced (Parc et al. 2000), since this exon contains
repeat sequences commonly altered in tumors with de-
fective DNA MMR (Yin et al. 1997; Iino et al. 2000).
These studies were performed with DNA isolated from
both leukocytes and fresh frozen tumor (when avail-
able).
Methylation Analysis
The methylation status of the promoter regions of
both hMLH1 and hMSH2 was assessed as described
elsewhere (Cunningham et al. 1998), using an HpaII-
based PCR assay. As a control for the PCR, a calcitonin
sequence devoid of HpaII sites was used. The hMLH1
and hMSH2 primers amplified fragments containing
HpaII-sensitive sites. DNA was first digested with the
restriction enzyme HpaII. The digested DNA was then
subjected to multiplex PCR; the products were electro-
phoresed on 8% polyacrylamide gels and then were an-
alyzed for the relative amplification of hMLH1 or
hMSH2 and calcitonin. The sizes of the unmethylated
PCR products were 114 bp, 107 bp, and 145 bp, for
hMLH1, hMSH2, and calcitonin, respectively. Ratios of
either hMLH1 or hMSH2 to calcitonin of !.2 indicated
no methylation (as in all the normal samples tested),
whereas a ratio of 1.8 was scored as positive for hy-
permethylation. Some samples had intermediate values
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Table 1
Patient Characteristics
SAMPLE (NO. AND %
OF TOTAL SAMPLE)
MEDIAN
AGE
(RANGE)a
(years)
NO. (%) OF INDIVIDUALS
Sexb Tumor Sitec Dukes Staged Age at Diagnosise
Male Female Proximal Distal A B C D 50 years 150 years
All Patients ( )Np 257 69 (29–91) 153 (59.0) 104 (41.0) 120 (46.7) 137 (53.3) 16 (6.2) 112 (43.6) 86 (33.5) 42 (16.7) 24 (9.3) 233 (90.7)
MSI-H ( , 19.8%)np 51 72 (35–91) 23 (45.1) 28 (54.9) 44 (86.3) 7 (13.7) 6 (11.8) 31 (60.8) 11 (21.6) 3 (5.9) 3 (5.9) 48 (94.1)
MSI-L ( , 7.0%)np 18 65.5 (29–84) 13 (72.2) 5 (27.8) 8 (44.4) 10 (55.6) 0 (0.0) 9 (50.0) 7 (38.9) 2 (11.1) 3 (16.7) 15 (83.3)
MSS ( , 73.2%)np 188 67 (34–90) 117 (62.2) 71 (37.8) 68 (36.2) 120 (63.8) 10 (5.3) 72 (38.3) 68 (36.2) 38 (20.2) 18 (9.6) 170 (90.4)
a (Kruskal-Wallis test).Pp .02
b (x2 test).Pp .05
c (x2 test).Pp .001
d (x2 test). Dukes Stage A—invasion limited to submucosa, with no nodal metastasis; B—invasion to at least the level of muscularis propria, with noPp .01
nodal metastasis; C—invasion at any level, with regional nodal metastasis but no distant metastasis; D—distant metastasis present (Astler and Coller 1954).
e (x2 test).Pp .39
and were considered to have either partial methylation
or hemimethylation.
Some of the samples were also examined using the
methylation-specific PCR (MSP) assay, as described by
Herman et al. (1998). These samples were also subjected
to DNA sequence analysis, after bisulfite treatment. For
the sequence analysis, the following primers for PCR
amplification and sequencing were designed to amplify
both methylated and unmethylated modified DNA, cor-
responding to the regions assessed in the HpaII (region
3) and MSP (region 2): using the U83845 sequence, re-
gion 3, forward 5′ position 339, tagattaggtatagggtttta
and reverse 5′ position 603, aaatataccaataaaaaca; region
2, forward 5′ position 158, gaggtttgtaygagtagtttt and
reverse 5′ position 381, ataaacacrttatttaat (r p a or g,
y p c or t). The underlined nucleotides represent those
cytosine residues that are converted to uracil/thymine (if
unmethylated) or are retained (if methylated) in themod-
ification. The PCRs were performed in 25-ml reactions
containing PCR buffer 1 (Perkin Elmer) with 1.5 mM
(region 3) or 2 mM (region 2) MgCl2, 10 pmol primer,
1.25 units AmpliTaq Gold (Perkin Elmer), and 1 ml bi-
sulfite-modified DNA (equivalent to 50 ng genomic
DNA). After an initial preheating step of 12 min at 95C,
PCR was performed over 40 cycles of 95C for 30 s,
55C for 30 s, and 72C for 30 s, with a final extension
at 72C for 30 min. PCR products were cleaned using
a HighPure PCR purification column (Boeringer Mann-
heim) and were sequenced with the forward primer used
in the initial PCR, on an ABI 377 (ABI Biosystems).
Methylation studies were performed with DNA isolated
from both leukocytes and fresh frozen tumor (when
available).
Results
Patient Sample
The clinical characteristics of the 257 participating
patients are shown in table 1. Patient ages at diagnosis
were 29–91 years (median 69 years), and the male-to-
female ratio was 1.47 (153 male, 104 female). For the
nonparticipants ( ), the male-to-female ratio wasnp 199
1.1 (102 male, 97 female; ), indicating thatPp .08
males were more likely to participate than females. The
nonparticipants were also slightly older than were the
participants (median age 73 vs. 69 years; ).Pp .0001
MSI and Immunohistochemistry
Of the 257 patients with CRC available for study, 51
(20%) were MSI-H, 18 (7%) were MSI-L, and 188
(73%) were MSS (table 1, fig. 1). All but one of theMSI-
H tumors and none of the MSI-L or MSS tumors dem-
onstrated MSI at BAT 26. Consistent with previous ob-
servations, significant associations were observed be-
tween tumors with the MSI-H phenotype and proximal
tumor location, female gender, and Dukes’ stage (table
1).
Protein expression for hMLH1, hMSH2, and hMSH6
was then examined in paraffin-embedded tissues (im-
munohistochemistry not shown; results summarized in
fig. 1). All 51 MSI-H tumors showed an absence of pro-
tein expression of either hMLH1 ( [94%]) ornp 48
hMSH2 ( [6%]). None of the tumors demon-np 3
strated an absence of hMSH6 only; however, all three
tumors lacking hMSH2, as well as one with an absence
of hMLH1, also showed an absence of hMSH6. All of
the MSI-L and MSS tumors demonstrated normal ex-
pression for all three of these proteins (two MSS tumors
were not scored for hMLH1, because of technical failure,
but had normal expression of hMSH2 and hMSH6). All
of the patients with FAP and CUC had normal protein
expression; one patient with FAP exhibited an MSI-L
phenotype, and the remaining patients exhibited anMSS
phenotype.
Mechanism of Gene Inactivation
DNA sequence analysis and promoter hypermethyl-
ation studies were used to explore the mechanisms un-
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Figure 1 Flow diagram for the results of testing of the 257 consecutive, unselected patients with CRC. Tumors were assessed for the
presence or absence of tumor MSI (MSI-H, MSI-L, or MSS); hMLH1, hMSH2, and hMSH6 protein expression (D indicates loss of expression);
hMLH1, hMSH2, and hMSH6 gene mutations; and hMLH1 and hMSH2 promoter hypermethylation.
derlying defective DNA MMR in the MSI-H patients
( ). Normal leukocyte DNA was available fornp 51
study from all 51 MSI-H patients; however, DNA from
fresh frozen tumor was available for study from only
44 of the 51 MSI-H patients (42 of 48 lacked hMLH1,
and 2 of 3 lacked hMSH2). Thus, all MSI-H patients
were examined for germline mutations, but only 44 of
the 51 patients were examined for somatic alterations
(tumor DNA sequencing and promoter methylation).
The single MSI-H patient that did not show instability
at BAT-26 was not examined for somatic alterations,
since no frozen tissue was available for DNA extraction
(this patient did not show evidence of any germline al-
teration in hMLH1).
Of the 48 patients lacking hMLH1 protein expression,
12 had hMLH1 gene alterations, 4 of whom had germ-
line alterations and 8 of whom had somatic alterations
only (table 2, fig. 1). Two of the four germline hMLH1
mutations were splicing alterations, which are likely to
be pathogenic, whereas the other two were missense
changes, which have unknown pathogenic consequences
(table 2). One of these missense mutations (in patient
209) occurred at a conserved codon and might therefore
have pathological consequences, whereas the other mu-
tation (in patient 83) occurred at a nonconserved site.
Two of the patients with germline mutations (patients
274 and 209) also demonstrated the presence of a so-
matic mutation in the tumor. Three of the eight tumors
with somatic hMLH1 alterations had mutations with
uncertain pathological consequences; of these three, two
were within introns (in patients 441 and 302) and one
resulted in a silent change (in patient 298). These three
mutations were analyzed with a splice-predictor pro-
gram at the Berkeley Drosophila Genome Project Web
site, and none of them were predicted to alter splicing.
Of the remaining five mutations, four would be expected
to result in truncated proteins (in patients 75, 53, 61,
and 91), and one was a missense alteration occurring at
a highly conserved codon (in patient 379).
All three tumors with an absence of hMSH2 expres-
sion had a germline hMSH2 mutation (table 2, fig. 1),
each of which would be expected to result in a truncated
product. Patient 46 also showed the presence of a so-
matic alteration.
In addition to those alterations described above, six
germline polymorphisms—four in hMLH1 and two in
hMSH2—were also noted (table 3). Three of the hMLH1
polymorphisms and both of the hMSH2 polymorphisms
have been described elsewhere (for a list of published
and unpublished mutations and polymorphisms, see the
Web site of the International Collaborative Group on
Hereditary Non-Polyposis Colorectal Cancer). The one
unreported hMLH1 sequence variant was a silent change
in exon 17 (leucine to leucine) and was found in only a
small number of cases.
The promoter regions of both hMLH1 and hMSH2
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Table 2
The Spectrum of Germline and Somatic Alterations in hMLH1 and
hMSH2
Gene, Mutation
Type, and
Patient Number Exon/Intron Nucleotide Changea Consequence
hMLH1:
Germline:
274 I6 IVS5-1, gra Splice site
21 I9 IVS91, gra Splice site
83 E12 1321 GrA A441T
209 E12 1217 GrA S406N
Somatic:
274 E7 583 del A G201 stop
274 E19 2146 GrA V716M
209 E8 677 GrA R226Q
75 E6 469 del T K160 stop
53 E7 583 del A G201 stop
61 E17 1912 GrT G638 stop
91 I16-E17 IVS17-7, del 17 bp Splice site
379 E18 2000 ArG D667G
298 E7 557 CrT H186H
441 I8 IVS816, del a Unknown
302 I11 IVS119, gra Unknown
hMSH2:
Germline:
46 I4 IVS41, gra Splice site
90 E8 1316-1317del CT T441 stop
403 E13 2038 CrT R680 stop
Somatic:
46 E7 1165 CrT R389 stop
a Lowercase letters indicate nucleotides in intron; uppercase letters
indicate nucleotides in exon.
Table 3
Spectrum of Germline Sequence Variants in hMLH1 and hMSH2
Gene and
Exon/Intron Nucleotide Changea Consequence Frequency
hMLH1:
E8 655 ArG I219V 19/48
I13 IVS1314, gra Unknown 2/48
I14 IVS15-19, arg Unknown 27/48
E17b 1959 GrT L653L 4/48
hMSH2:
I9 IVS10-9, tra Unknown 3/3
I12 IVS13-6, trc Unknown 1/3
a Lowercase letters indicate nucleotides in intron; uppercase letters
indicate nucleotides in exon.
b Not previously reported.
were initially examined for hypermethylation through
use of an HpaII-based PCR assay. Forty-four MSI-H
tumors were examined, 42 of 48 for hMLH1 and 2 of
3 for hMSH2. Hypermethylation of the hMSH2 pro-
moter was not detected for the MSI-H/hMSH2–negative
tumors tested. Of the MSI-H/hMLH1–negative tumors,
34 demonstrated hMLH1 hypermethylation by the
HpaII-based PCR assay. Three MSI-H tumors lacked
expression of hMLH1 but had no detectable hMLH1
mutations and did not exhibit hMLH1 hypermethyla-
tion by the HpaII assay. We examined these 3 tumors,
as well as another 17 that did show promoter hyper-
methylation by the HpaII assay, for methylation, using
the MSP assay. The 3 tumors that did not show evidence
of hypermethylation with the HpaII assay now showed
evidence of methylation with the MSP assay, and the
methylation status of the other 17 tumors was con-
firmed.
To further explore the molecular basis for the differ-
ences between the three discordant cases, the hMLH1
5′ regions examined by the two assays (HpaII site, region
3, and MSP, region 2) were sequenced using bisulfite-
modified DNA. For all three of these cases, all CpG sites
were methylated, with the exception of the HpaII site.
Thus, 37 of 42 tumors (88%) demonstrated promoter
hypermethylation for hMLH1. Four tumor samples had
both mutations in hMLH1 and hypermethylation (fig.
1). Two of these mutations were missense changes, and
two were frameshifts; three were somatic, and one was
a germline alteration. The one germline alteration was
a missense change at a nonconserved site (in patient 83).
All of the tested tumors lacking a germline or somatic
alteration showed evidence of promoter hypermethyla-
tion (30/30). Thus, all of the MSI-H tumors tested that
lacked hMLH1 expression had either hypermethylation
and/or a mutation in hMLH1.
Analysis of hMSH6
Three of four available tumors that lacked hMSH6
expression were examined for the presence of a mutation
in exon 5 of hMSH6. Patient 46 had a C insertion, and
case 83 had both a C insertion and a C deletion within
the C(8) repeat. Patient 19 showed the presence of an
ins3405T mutation. All of these alterations are somatic,
and all result in a frameshift.
Defective MMR and a Family History of CRC
Forty-seven (92%) of the MSI-H patients, all 18
(100%) of the MSI-L patients, and 160 (85%) of the
MSS patients had family histories available for review.
Of the 225 unrelated patients, 7 (3.1%) fulfilled the AC
for HNPCC. Defective DNA MMR was noted in four
of these seven individuals. Of the four patients with de-
fective MMR, three were found to have germline de-
fects—one in hMLH1 (patient 274) and two in hMSH2
(patients 46 and 403)—whereas the other tumor (in pa-
tient 19) demonstrated only hMLH1 hypermethylation.
It is possible that this tumor does indeed harbor a germ-
line alteration not detected by our sequencing strategy.
Notably, three of the seven tumors from patients with
HNPCC did not exhibit evidence of defective DNA
MMR. An additional two patients fulfilled the modified
AC for HNPCC, only one of whom had an MSI-H tu-
mor. No additional germline alterations were identified.
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Table 4
Family Characteristics of Patients with Germline Mutations
MUTATION TYPE
AND PATIENT
NUMBER
GERMLINE
MUTATION
AGE
AT
ONSET
(years)
MULTIPLE
CRC IN
PROBAND
NO. OF CRC CASES IN
NO. OF OTHER
HNPCC CANCERS
IN FAMILYa
TOTAL NO. OF
CRC CASES
IN FAMILY
First-Degree
Relatives
Second-Degree and
Higher Relatives
Pathogenic:
274b hMLH1 IVS5-1 35 Yes 4 3 0 8
21 hMLH1 IVS91 68 No 2 NK NK 3
46b hMSH2 IVS41 44 No 1 7 0 9
90 hMSH2 T441stop 35 No 0 0 0 1
403b hMSH2 R680stop 55 No 0 4 0 5
Uncertain
pathogenicity:
83 hMLH1 A441T 82 No NK NK NK NK
209 hMLH1 S406N 65 No 0 0 0 1
NOTE.—NK p not known. In the case of patient 83, no family history was available, and, in the case of patient 21, only limited history
was available.
a Includes cancer of the endometrium, ovary, stomach, renal pelvis, ureter, and small bowel, in first-degree and higher relatives.
b Patient fit the AC.
The family characteristics of those patients with germ-
line mutations are presented in table 4. Only three (pa-
tients 46, 274, and 403) of the seven patients with germ-
line mutations fulfilled the AC. Two of these patients
were aged !50 years (patients 35 and 44) at first diag-
nosis; the third was aged 55 years. Patient 403, who had
a truncating hMSH2 mutation, had a father who de-
veloped stomach cancer at age 38 years. Although pa-
tient 403 was not in a branch of the family that satisfied
the AC, additional individuals on the paternal side of
the family (aunt, uncle, cousin, and second cousin) had
CRC, satisfying the AC for this family branch. We were
not able to obtain family-history information for the one
patient (patient 83) with a tumor that was associated
with a germline missense hMLH1 mutation. This was
also the only tumor from a germline mutation–bearing
patient that exhibited hMLH1 hypermethylation. One
additional patient (patient 21) had no documented fam-
ily history, and two patients (patients 90 and 209) had
no indication of a family history of either CRC or ex-
tracolonic HNPCC tumors.
Discussion
There has been considerable discussion about both the
frequency of HNPCC and the means of identifying these
individuals. The purpose of the present prospective study
was to determine the frequency of inherited defects in
DNA MMR (which we will refer to as “hereditary de-
fective mismatch repair syndrome” or HDMMR), which
is one particular cause of HNPCC. This was a prospec-
tive study in which all consenting surgical cases of CRC
were examined for evidence of defective DNA MMR,
without prior selection based on family history.
Overall, evidence of defective DNAMMRwas found
in 20% of the 257 patients with CRC. This is within
the range (12%–24%) previously published for colo-
rectal cancer (Ionov et al. 1993; Thibodeau et al. 1993;
Nakashima et al. 1997). All of the tumors with evidence
of MSI-H (a phenotypic indicator of defective MMR)
had altered protein expression of either hMLH1 or
hMSH2. Abnormal protein expression for these two
genes was not found in the remaining tumors. Further-
more, in the overall group of patients, absence of
hMSH6 occurred only in the context of an abnormality
in hMSH2 or hMLH1. Thus, it is likely that all cases
of defectiveMMR that involve (a) hMSH2, (b) hMLH1,
(c) hMSH6, and/or (d) an MSI phenotype have been
identified in this group of patients.
Unequivocal pathogenic (truncating) germline mu-
tations were identified in five patients, and missense
germline mutations of unknown significance were iden-
tified in two additional patients. Thus, in this cohort of
patients, the incidence of hereditary defective MMR is
∼2%. This may be an underestimate, since we did not
test for the presence of large deletions, which have been
noted to occur (Wijnen et al. 1998). However, our find-
ings suggest that the true frequency of HDMMR in this
group of patients is not likely to be much higher, since
somatic mutations and/or hypermethylation of the
hMLH1 promoter appears to account for the MSI-H
phenotype in all of the remaining tumors. Although the
Finnish study by Aaltonen et al. (1998) found a some-
what lower proportion of CRC to have defective DNA
MMR (12% of cases), the frequency of germline
hMSH2 and hMLH1 mutations was similar to that
found in the present study. In the study by Aaltonen et
al. (1998), tumors were screened for MSI but mutations
were tested for in hMSH2 or hMLH1 only; hMSH6
was not examined. Additionally, immunohistochemical
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analysis was not included in their study. Cumulatively,
these two studies suggest that the frequency of inherited
defects in MMR in a population of patients with CRC
referred for surgery is ∼2%. The present study is the
first large study in the United States that has looked at
the frequency of disease in an unselected group of pa-
tients who were referred for CRC resection and inwhich
no known founder mutations are described.
The germline mutations detected in the present study
would be expected to produce a truncated or altered
protein in all of the hMSH2 and in two of the four
hMLH1 cases. The remaining two hMLH1 alterations
were missense changes; one of these mutations occurred
in a highly conserved codon (S406N). Recent evidence
indicates that some missense hMLH1 mutations can af-
fect the interaction of hMLH1 with hPMS2 (Guerrette
et al. 1999); however, neither of the germline missense
mutations identified in the present study occurred in this
critical region. Nonetheless, the tumor with the S406N
missense alteration also had a second somatic missense
mutation, suggesting the possibility that this germline
alteration may have functional consequences. The sec-
ond missense alteration (A441T) occurred at a noncon-
served codon. This tumor also exhibited hMLH1 pro-
moter hypermethylation and, given the late age at onset
for the patient (age 82 years), the A441T more likely
represents a rare normal variant rather than a causative
mutation. At this point, however, functional studies
would be needed to distinguish between these two
possibilities.
There is no clear consensus about how best to identify
patients to be tested for HNPCC. Aaltonen et al. (1998)
suggested that either family history, young age at di-
agnosis, or a history of multiple CRC or related cancers
warranted testing for defective DNA MMR. This po-
sition was challenged in an editorial (Lynch and Smyrk
1998), which argued that family history alone may be
the most appropriate means of identifying HNPCC. In
the present study, tumors from three of the seven pa-
tients fulfilling the AC did not exhibit evidence of de-
fective DNA MMR; germline defects were evident in
only three of the patients with defectiveMMR. A fourth
patient with defective MMR may have a mutation not
detected by the methods employed in the present study.
It is likely, therefore, that other genes not involving
MMR are responsible for the colorectal cancer in the
three patients with HNPCC who have normal MMR.
Additionally, neither of the two additional patients sat-
isfying the modified ACwere found to harbor a germline
alteration. Conversely, when the family characteristics
of the patients with germline mutations were examined,
only three of seven patients fulfilled the AC. It is be-
coming increasingly apparent that not all individuals
fulfilling the AC or modified AC for HNPCC will have
inherited defects in DNAMMR, and not all individuals
with inherited defects have a strong family history of
cancer. HDMMR is a genetic diagnosis based on the
finding of defective DNA MMR in the tumor and of a
germline mutation in one of the DNA MMR genes,
whereas HNPCC is a clinical diagnosis. Not all patients
with HNPCC will have HDMMR, and not all patients
with HDMMR will fulfill the AC (or other clinical cri-
teria) for HNPCC. However, HDMMR is likely to be
a more homogenous entity (despite allelic heterogene-
ity), unlike HNPCC, which is heterogeneous and prob-
ably includes cases of HDMMR, other hereditary forms
of colorectal cancer (some for which the genes may not
have identified), and the chance familial clustering of
patients with sporadic colorectal cancer. It may be im-
portant to think about and treat these two syndromes
as different entities. The Bethesda guidelines (Rodri-
guez-Bigas et al. 1997) may improve the predictive po-
tential for identification of patients with defective DNA
MMR genes over that provided by family history alone
(Pistorius et al. 2000), since they take both the clini-
copathological and family characteristics into account.
We will report on the use of these guidelines, within
this data set, in a future article.
Interestingly, all of the hMSH2-deficient cases were
the result of a germline mutation. Although there are
only three cases in the series, the data suggest that an
absence of hMSH2 protein expression in CRC, when
detected, is predictive of the presence of a germline mu-
tation. Larger studies will be required to confirm such
findings. It is also interesting to note that hMSH6 pro-
tein expression was lost in all three hMSH2 cases, but
in only one of the hMLH1 cases. Our data suggest that,
in such cases, the loss of hMSH6 is secondary to a
mutation in either hMLH1 or hMSH2, a result which
supports the work of others (Wu et al. 1999; Planck et
al. 2000). The complete concordance for loss of hMSH2
and hMSH6 is most likely due to the physical proximity
of these two genes on chromosome 2. A germline mu-
tation in hMSH2 could be followed by loss of the second
allele, by a gross chromosomal event. Such an event
would also eliminate one normal hMSH6 allele. Defec-
tive MMR resulting from loss of hMSH2 could then
lead to instability of the hMSH6 poly C tract in exon
5 and subsequent inactivation of the second allele. As
before, additional studies will be required to test this
hypothesis.
In summary, whereas the frequency of defective DNA
MMR in this referral-based study was found to be rel-
atively common (20%), the frequency of inherited de-
fects (HDMMR) was found to be low (∼2%). The pri-
mary mechanism of DNA MMR gene inactivation
appears to be epigenetic, with hMLH1 hypermethyla-
tion occurring in 100% of hMLH1-negative MSI-H tu-
mors without detectable mutations. Two conclusions
can be drawn from the family history information. First,
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although a strong family history correlates with the
presence of germline mutations, it did not identify all
the potential at-risk individuals. Second, with only four
of seven patients with HNPCC having evidence of de-
fective MMR (and none of those having a family history
of HNPCC-related tumors), it is clear that there must
be other factors that predispose to cancer development
in these families. Molecular techniques can help in the
identification of patients with defects in DNA MMR
and can be used to complement family history and other
guidelines in the clinical setting. This will greatly facil-
itate the diagnosis of HDMMR and the identification
of individuals at high risk of cancer development.
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